research use only

MCC950 Sodium NLRP3 inhibitor

Cat.No.S7809

MCC950 Sodium is a potent, selective inhibitor of NLRP3 with IC50 of 7.5 nM in BMDMs; but not the AIM2, NLRC4 or NLRP1 inflammasomes.
MCC950 Sodium NLRP3 inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 426.46

Quality Control

Cell Culture, Treatment & Working Concentration

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
mouse BMDM cells Function assay 30 mins Inhibition of NLRP3 in mouse BMDM cells preincubated for 30 mins followed by ATP addition by ELISA analysis. IC50=0.0075 μM 26422006
mouse BMDM cells Function assay 30 mins Inhibition of NLRP3 inflammasome activation in LPS-stimulated mouse BMDM assessed as reduction in NLRP3 inflammasome-induced IL-1beta production preincubated for 30 mins followed by NLRP3 stimulation with ATP by ELISA. IC50=0.0075 μM 27994733
INS-1 cells Function assay 0.01 μM 1 h MCC950 inhibited not only inflammasome activation but also Ang II-induced IL-1β elevation and cell apoptosis in INS-1 cells. 30939192
16HBE cells Cell viability assay 0.01, 0.1, 1, 10, 100 μM 24, 48, 72h 100μM MCC950 functionally alleviated silica-induced activation of NLRP3 inflammasome in 16 HBE cells. 29258746
THP-1 monocytes Function assay 1 μM 30 mins Pretreatment of THP‐1 monocytes for 30 min with this compound resulted in a significant reduction in IL‐1β release, but not pyroptosis upon transfection with LPS. 26173988
macrophages Function assay 30 mins Inhibition of NLRP3 in human monocyte derived macrophages assessed as reduction in LPS-induced IL-1beta production incubated for 30 mins followed by nigericin sodium salt stimulation for 2 hrs post LPS challenge for 3 hrs by ELISA, IC50 = 0.005 μM. 29338910
macrophages Function assay Inhibition of NLRP3 in human monocyte derived macrophages assessed as reduction in LPS-induced IL-1beta production by ELISA, IC50 = 0.008 μM. 29338910
Click to View More Cell Line Experimental Data

Chemical Information, Storage & Stability

Molecular Weight 426.46 Formula

C20H23N2O5S.Na

Storage (From the date of receipt)
CAS No. 256373-96-3 Download SDF Storage of Stock Solutions

Synonyms CP-456773 Sodium, CRID3 Sodium Smiles CC(C)(C1=COC(=C1)S(=O)(=O)[N-]C(=O)NC2=C3CCCC3=CC4=C2CCC4)O.[Na+]

Solubility

In vitro
Batch:

Water : 43 mg/mL

Ethanol : 43 mg/mL

DMSO : Insoluble ( Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
NLRP3 [1]
(in BMDM (bone marrow derived macrophages))
7.5nM
NLRP3 [1]
(in HMDM)
8.1 nM
In vitro

MCC950 inhibits canonical and noncanonical NLRP3 activation in BMDM and HMDM cells at IC50 of 7.5 and 8.1nM. MCC950 specifically inhibits activation of NLRP3 but not the AIM2, NLRC4 or NLRP1 inflammasomes.[1]

In vivo

MCC950 reduces interleukin-1β (IL-1β) production and attenuates the severity of experimental autoimmune encephalomyelitis (EAE). Furthermore, MCC950 treatment rescues neonatal lethality in a mouse model of CAPS and is active in ex vivo samples from individuals with Muckle-Wells syndrome. [1]

References

Applications

Methods Biomarkers Images PMID
Western blot NLRP3 / Casp-1 / BMI1 / ALDH1 / CD44 S7809-WB1 28865486
Growth inhibition assay Cell viability S7809-viability1 27670879
Immunofluorescence ALDH1 / BIM1 / CD44 S7809-IF1 28865486
ELISA IL-1β S7809-ELISA1 28726778

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.